Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study

AIM: To confirm the efficacy and safety of bevacizumab/XELOX combination for the treatment of locally advanced or metastatic colorectal cancer (CRC) in Italy. METHODS: This multicentric, prospective, open-label study included patients with CRC previously untreated with chemotherapy. Patients were ad...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:World J Gastroenterol
Main Authors: Antonuzzo, Lorenzo, Giommoni, Elisa, Pastorelli, Davide, Latiano, Tiziana, Pavese, Ida, Azzarello, Domenico, Aieta, Michele, Pastina, Ilaria, Di Fabio, Francesca, Bertolini, Alessandro, Corsi, Domenico Cristiano, Mogavero, Selene, Angelini, Valentina, Pazzagli, Mario, Di Costanzo, Francesco
פורמט: Artigo
שפה:Inglês
יצא לאור: Baishideng Publishing Group Inc 2015
נושאים:
Prospective Study
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4476891/
https://ncbi.nlm.nih.gov/pubmed/26109816
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v21.i23.7281
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים